OPTOA
Opthea Limited
π¦πΊ ASX
π Overview
π Performance
π΅ Cost
π€ Advanced
π¨βπ©βπ§βπ¦ Community
π
N/A
Annual Growth
5 years average annual growth
π΅
$ 500
Minimum Order
Due to regulatory requirements
π
1
Pearlers Invested
Since January 2020
π Overview
Key information
π Fund Overview
Opthea Limited - Option Expiring 31-Aug-2025
π Performance
Price History
N/A
1M
1Y
All Time
Graph
Table
Unsure how much or often to invest?
ποΈ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out βπ΅ Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out ββ±οΈ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out βπ΅ Costs
πΌ
N/A
Management Fee
Included in unit price, not charged by Pearler
πΈ
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
πΈ Net fee calculatorπ€ Advanced information
Technical Info
π° Price*
$0.41
*Price may be up to 24 hours old
π©βπ©βπ¦ Community Insights
How our community is investing
π Pearlers invested in OPTOA
1
π Total Capital Earnings
N/A
π Average investment frequency
9 weeks
π΅ Average investment amount
$3,644
β° Last time a customer invested in OPTOA
179 days
OPTOA investor breakdown
π΅ Income of investors
More than 200k
50%
150k - 200k
100k - 150k
50k - 100k
Less than 50k
50%
πΆ Age of investors
18 - 25
26 - 34
35 - 90
100%
π Legal gender of investors
Female
Male
100%
Pearlers who invest in OPTOA also invest in...
ASIA.AX was created on 2018-09-18 by BetaShares. The fund's investment portfolio concentrates primarily on information technology equity. The investment objective of the BetaShares Asia Technology Tigers ETF is to provide an investment return that aims to track the performance of the Solactive Asia ex-Japan Technology & Internet Tigers Index (the Index), before taking into account fees and expenses.
π Performance (5Yr p.a)
9.76%
π Share price
$9.82 AUD
π HIGH PRICE GROWTH
π¦πΊ EX AUSTRALIA
VGS.AX was created on 2014-11-18 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard MSCI International Shares Index ETF seeks to track the return of the MSCI World ex-Australia Index (with net dividends reinvested) in Australian dollars before taking into account fees, expenses and tax.
π Performance (5Yr p.a)
12.86%
π Share price
$129.54 AUD
π GLOBAL
β³οΈ DIVERSIFIED
π€ TECHNOLOGY
π HIGH PRICE GROWTH
NDQ.AX was created on 2015-05-26 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. The fund aims to track the performance of the NASDAQ-100 Index (before fees and expenses). The NASDAQ-100 comprises 100 of the largest non-financial companies listed on the NASDAQ market, and includes many companies that are at the forefront of the new economy.
π Performance (5Yr p.a)
24.88%
π Share price
$45.04 AUD
π€ TECHNOLOGY
π HIGH PRICE GROWTH
πΊπΈ UNITED STATES
Opthea Ltd. is a clinical stage biopharmaceutical company, which engages in the development of biological therapeutics for the treatment of progressive retinal diseases. The company is headquartered in Melbourne, Victoria. The firm is engaged in developing novel therapies to address the unmet need in the treatment of prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Its lead product candidate, sozinibercept (OPT-302), is being evaluated in two pivotal Phase 3 clinical trials for use in combination with standard-of-care anti-VEGF-A monotherapies for the treatment of wet AMD and DME. The firm has also manufactured OPT-302 for use in Phase III clinical trials, conducts activities to support the commercialization of the product and expanded its management team in the United States to facilitate broader oversight and execution of its Phase III program. Its development activities are based on an intellectual property portfolio covering key targets (Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3).
π Performance (5Yr p.a)
-15.21%
π Share price
$0.80 AUD
𧬠BIOTECHNOLOGY
VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.
π Performance (5Yr p.a)
3.85%
π Share price
$100.90 AUD
β³οΈ DIVERSIFIED
π¦πΊ AUSTRALIA
𧱠MATERIALS
πΈ FINANCIALS
Want more shares? Try these...
Orora Ltd. engages in the manufacturing and distribution of fiber, glass and aluminum beverage cans. The company is headquartered in Hawthorn, Victoria and currently employs 4,657 full-time employees. The company went IPO on 2013-12-18. The company supplies packaging products and services to the grocery, fast moving consumer goods and industrial markets. The Companyβs Australasia segment focuses on the manufacture of beverage packaging products within Australia and New Zealand. Its North America segment is predominately located in North America, which purchases, warehouses, sells and delivers a range of packaging and other related materials. The business also includes integrated corrugated sheet and box manufacturing and equipment sales capabilities and point of purchase retail display solutions and other visual communication services. Its Saverglass business is engaged in the design, manufacturing, customization and decoration of high-end bottles and provides for the premium and super-premium spirits, fine wine and champagne markets.
π Performance (5Yr p.a)
-8.00%
π Share price
$2.37 AUD
π° HIGH DIVIDEND
ποΈ SOCIALLY AWARE
π¦ LOGISTICS
Opthea Ltd. is a clinical stage biopharmaceutical company, which engages in the development of biological therapeutics for the treatment of progressive retinal diseases. The company is headquartered in Melbourne, Victoria. The firm is engaged in developing novel therapies to address the unmet need in the treatment of prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Its lead product candidate, sozinibercept (OPT-302), is being evaluated in two pivotal Phase 3 clinical trials for use in combination with standard-of-care anti-VEGF-A monotherapies for the treatment of wet AMD and DME. The firm has also manufactured OPT-302 for use in Phase III clinical trials, conducts activities to support the commercialization of the product and expanded its management team in the United States to facilitate broader oversight and execution of its Phase III program. Its development activities are based on an intellectual property portfolio covering key targets (Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3).
π Performance (5Yr p.a)
-15.21%
π Share price
$0.80 AUD
𧬠BIOTECHNOLOGY